-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
10x Genomics recently reported that its operating income in the third quarter reached US$125 million, an increase of 74% year-on-year from US$71.
The company’s consumables revenue in the third quarter reached US$106 million, a year-on-year increase of 75%; instrument revenue was US$17.
By region, revenue in the Americas was US$70.
Serge Saxonov, CEO of 10x, said: "Our team achieved strong results this quarter, successfully launched Chromium X, and managed this complex operating environment
Subsequently, some 10x executives explained these complexities in detail
First-time financial officer Justin McAnear said that 10x’s business faces “increasing downside risks”, adding that these risks have affected consumables revenue this quarter
The company’s net loss for the quarter narrowed to US$17.
10x Genomics' research and development expenses increased from US$30.
As of September 30, 10x Genomics had a total of US$600 million in cash and cash equivalents
McAnear said that despite the challenging environment, the company is still expected to achieve strong performance at the end of this year